PSCA

PSCA Molekülinformation

Englischer Name	Prostate stem cell antigen	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	4	Target-Alias	Prostate stem cell antigen，UNQ206/PRO232，PSCA，PRO232
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

Englischer Name	Prostate stem cell antigen
Target-Alias	Prostate stem cell antigen，UNQ206/PRO232，PSCA，PRO232
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	4
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

PSCA Produktliste

Attribut
Protein (5)
Produktbibliothek
Online (5)
Spezies
Human (4)Mouse (1)
Etikett
His Tag (3)His Tag & Avi Tag (2)
Marker
Unconjugated (1)Biotin-labeled (2)PE Labeled (1)AF488 Labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT PSA-H52H6	Human	HEK293	Human PSCA Protein, His Tag	In den Warenkorb legen
HOT PSA-H82E3	Human	HEK293	Biotinylated Human PSCA Protein, His,Avitag™ (MALS verified)	In den Warenkorb legen
PSA-HA2H3	Human	HEK293	Alexa Fluor™ 488-Labeled Human PSCA Protein, His Tag (Site-specific conjugation)	In den Warenkorb legen
PSA-HP2H3	Human	HEK293	PE-Labeled Human PSCA Protein, His Tag (Site-specific conjugation)	In den Warenkorb legen
PSA-M82Ea	Mouse	HEK293	Biotinylated Mouse PSCA Protein, His,Avitag™, low endotoxin (MALS verified)	In den Warenkorb legen

Gesamtmenge5

PSCA Molekülhintergrund

The Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored protein, plays an important role in tumorigenesis. The prostate stem cell antigen (PSCA) gene, which encodes a prostate-specific antigen (PSA), was identified as a gene involved in cell adhesion and proliferation. PSCA may be involved in the regulation of cell proliferation. Has a cell-proliferation inhibition activity in vitro. May act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro inhibits nicotine-induced signaling probably implicating alpha-3:beta-2- or alpha-7-containing nAChRs.

PSCA Molekülalias

PSCA,UNQ206,PRO232

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (City of Hope Medical Center)		Phase 1 Clinical	City Of Hope National Medical Center	Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant	Details
124-iodine-labeled PSCA targeting minibody (ImaginAb)		Phase 1 Clinical	University Of California At Los Angeles	Pancreatic Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms	Details
anti-PSMA/anti-PSCA CAR T-cell therapy PD-1 silent (Shanghai Unicar-Therapy Bio-medicine)		Phase 1 Clinical	Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd	Hormone-Resistant Prostate Neoplasms	Details
MB-104	MB-104; MB-105; MB-104 CS1 CAR; MB-105 PSCA CAR	Phase 1 Clinical	City Of Hope National Medical Center	Glioblastoma; Multiple Myeloma; Pancreatic Neoplasms; Prostatic Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms	Details